_version_ 1785128582922633216
author Opalinska, Marta
Lezaic, Luka
Decristoforo, Clemens
Kolenc, Petra
Mikolajczak, Renata
Studen, Andrej
Simoncic, Urban
Virgolini, Irene
Trofimiuk-Muldner, Malgorzata
Garnuszek, Piotr
Rangger, Christine
Fani, Melpomeni
Glowa, Boguslaw
Skorkiewicz, Konrad
Hubalewska-Dydejczyk, Alicja
author_facet Opalinska, Marta
Lezaic, Luka
Decristoforo, Clemens
Kolenc, Petra
Mikolajczak, Renata
Studen, Andrej
Simoncic, Urban
Virgolini, Irene
Trofimiuk-Muldner, Malgorzata
Garnuszek, Piotr
Rangger, Christine
Fani, Melpomeni
Glowa, Boguslaw
Skorkiewicz, Konrad
Hubalewska-Dydejczyk, Alicja
author_sort Opalinska, Marta
collection PubMed
description
format Online
Article
Text
id pubmed-10611881
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106118812023-10-29 Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor Opalinska, Marta Lezaic, Luka Decristoforo, Clemens Kolenc, Petra Mikolajczak, Renata Studen, Andrej Simoncic, Urban Virgolini, Irene Trofimiuk-Muldner, Malgorzata Garnuszek, Piotr Rangger, Christine Fani, Melpomeni Glowa, Boguslaw Skorkiewicz, Konrad Hubalewska-Dydejczyk, Alicja Eur J Nucl Med Mol Imaging Image of the Month Springer Berlin Heidelberg 2023-07-15 2023 /pmc/articles/PMC10611881/ /pubmed/37452871 http://dx.doi.org/10.1007/s00259-023-06335-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Image of the Month
Opalinska, Marta
Lezaic, Luka
Decristoforo, Clemens
Kolenc, Petra
Mikolajczak, Renata
Studen, Andrej
Simoncic, Urban
Virgolini, Irene
Trofimiuk-Muldner, Malgorzata
Garnuszek, Piotr
Rangger, Christine
Fani, Melpomeni
Glowa, Boguslaw
Skorkiewicz, Konrad
Hubalewska-Dydejczyk, Alicja
Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
title Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
title_full Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
title_fullStr Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
title_full_unstemmed Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
title_short Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
title_sort comparison of 99mtc radiolabeled somatostatin antagonist with [(68) ga]ga-dota-tate in a patient with advanced neuroendocrine tumor
topic Image of the Month
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611881/
https://www.ncbi.nlm.nih.gov/pubmed/37452871
http://dx.doi.org/10.1007/s00259-023-06335-9
work_keys_str_mv AT opalinskamarta comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT lezaicluka comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT decristoforoclemens comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT kolencpetra comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT mikolajczakrenata comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT studenandrej comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT simoncicurban comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT virgoliniirene comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT trofimiukmuldnermalgorzata comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT garnuszekpiotr comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT ranggerchristine comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT fanimelpomeni comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT glowaboguslaw comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT skorkiewiczkonrad comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor
AT hubalewskadydejczykalicja comparisonof99mtcradiolabeledsomatostatinantagonistwith68gagadotatateinapatientwithadvancedneuroendocrinetumor